In the last days of September 1982, people in the Chicago area began dying suddenly. The first was a 12-year-old girl named Mary Kellerman. Within a short time, seven people were dead, including three members of one family, the Janus family. Investigators traced every death to the same thing: Extra-Strength Tylenol capsules that someone had laced with cyanide. Tylenol was not a minor product. It held about 35 percent of the billion-dollar American market for over-the-counter pain relievers, the most trusted name on the shelf. Overnight, that name was linked to murder.
James Burke had joined Johnson & Johnson in 1953 and had been its chairman and chief executive since 1976. The company had not poisoned anyone. Investigators came to believe the capsules had been tampered with after they left the factory and reached store shelves. That gave Burke a defensible way out. He could have treated the deaths as a local criminal act, cooperated with police, issued careful statements, and kept the brand on shelves everywhere else in the country. Plenty of executives would have called that responsible.
Burke had something to steer by that most executives do not. In 1943, Robert Wood Johnson, the man who built the modern company, had written a one-page document called Our Credo. It set out the company's responsibilities in a deliberate order. The first belonged to the people who used its products and the doctors and nurses who served them. Employees came next, then communities. Stockholders came last. The Credo's argument was that if the company got the first three right, the stockholders would be rewarded too.
Burke had spent years making sure that document meant something before anyone needed it. He started what the company called Credo Challenge meetings, in which managers were pushed to debate whether the Credo still made sense and how it applied to the business as it actually was. He reportedly told managers that if they were not going to live by it, they should take it off their walls. By the fall of 1982, the company's leaders had already argued about these priorities and committed to them. They did not have to invent their values in the middle of a crisis.
Burke took personal charge. Johnson & Johnson stopped advertising Tylenol and halted capsule production, and Burke met with the FBI and the Food and Drug Administration. He leaned toward a broad recall, but the officials initially pushed back. The FBI worried that a nationwide recall would hand the killer a victory, and the FDA worried it would spread more fear than it relieved. After a copycat poisoning was reported in California, the FDA agreed. On October 5, 1982, Johnson & Johnson recalled Tylenol capsules nationwide, about 31 million bottles with a retail value of more than $100 million.
The cost was immediate and severe. Tylenol's sales dropped by roughly 80 percent, and its share of the market fell from about 35 percent to around 8 percent. Johnson & Johnson's third-quarter earnings fell from 78 cents a share to 51 cents. At the time, it was far from clear that the brand could survive at all. Burke was spending the company's money to protect people who would never know his name, in towns that had seen no poisonings.
Then he set out to make the product safer than it had ever been. By November 1982, Tylenol was back on shelves in a new triple-sealed, tamper-resistant package. The company sent more than 2,200 salespeople to talk directly with doctors and pharmacists. The changes spread well beyond one brand. Congress made product tampering a federal crime, and the FDA required tamper-resistant packaging on over-the-counter drugs. The foil seals and shrink bands that people now peel off without a thought trace back to this moment.
Tylenol came back. Within a few years it had regained its position as the leading pain reliever, and the company's handling of the crisis became a standard case in business schools. Under Burke's leadership, Johnson & Johnson's revenue roughly tripled to more than $9 billion. In 2000, President Bill Clinton awarded him the Presidential Medal of Freedom, largely for his later work leading the Partnership for a Drug-Free America.
The story did not end cleanly, and that is part of its lesson. In February 1986, a 23-year-old woman named Diane Elsroth died in New York after taking Tylenol capsules laced with cyanide, despite the new packaging. Burke concluded that no seal could fully protect a capsule once it left the plant. Johnson & Johnson stopped selling over-the-counter capsules altogether, a decision that cost about $150 million. Burke said the company acted "with great reluctance and a heavy heart." The 1982 murders were never solved. Integrity sometimes asks you to pay twice.
Most managers will never face a poisoning. But nearly every manager faces smaller versions of Burke's choice. A defect you could quietly fix in the next batch. An error a customer will probably never notice. A shortcut that is technically within the rules. In each case there is a defensible answer and a right answer, and they are not always the same. Johnson & Johnson could have defended a recall limited to Chicago. Burke chose the answer he could not be ashamed of.
You can prepare for that moment on Monday. Write down, in plain language, the order of responsibilities your team serves, and put the people who depend on your work at the top. Talk about it when nothing is on fire. Ask your team, openly, where you are not living up to it. And when something goes wrong, make the first question, "Who could be hurt, and what do they need from us?" Count the cost second.
Burke did not discover his values in October 1982. He had been rehearsing them for years, in meetings where managers argued over a single page until they believed it. That is why he could move fast when it counted. Integrity is not what hangs on the wall. It is what you are willing to pull off the shelf.